Artificial intelligence (AI), particularly Generative AI (GenAI), is reshaping how private equity (PE)-backed portfolio companies approach product development. By moving teams away from manual, sequential workflows and toward more automated, predictive, and efficient operating models, AI has the potential to improve performance across the software development life cycle (SDLC).

For many companies, traditional product and software development processes are no longer aligned with the speed, predictability, and capital efficiency required during compressed hold periods. PE-backed businesses need practical ways to reduce delivery friction, improve execution, and create measurable value.

For PE firms, AI adoption is more than an operational enhancement. Applied thoughtfully across the development lifecycle, it can help accelerate time to market, improve product quality, reduce operating costs, and support stronger exit outcomes.

This case study explores how the pragmatic application of GenAI can unlock meaningful value across product management and the SDLC. Rather than focusing on code generation alone, the approach highlights how GenAI can improve knowledge sharing, enhance implementation, reduce defect resolution time, and help teams move from ideation to execution more effectively.

Learn how a PE-backed healthcare technology platform applied GenAI to improve product management and software development life cycle execution.

Read the Second Case Study

Explore the first case study in the Navigating the Tech Terrain series for another perspective on how GenAI can help technology organizations improve performance.

Read the First Case Study